Actavis signs option to acquire relamorelin developer

22 October 2014
mergers-acquisitions-big

Ireland-headquartered Actavis (NYSE: ACT) has been granted an exclusive option to acquire USA-based biopharma company Rhythm Pharmaceutical's wholly-owned subsidiary, Rhythm Health Inc, which is developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other gastro-intestinal (GI) functional disorders.

Rhythm has completed a successful Phase II trial of relamorelin for the treatment of diabetic gastroparesis and a second successful Phase II study for chronic constipation. Rhythm expects to initiate a Phase IIb clinical trial for the treatment of diabetic gastroparesis by early 2015.

Terms include an upfront $40 million

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical